Tokyo, Oct. 9 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059341) titled 'A Prospective, Real-World Study Evaluating the Impact of RISankizumab on BurdEn of Disease in Ulcerative Colitis in JaPan (RISE UP)' on Oct. 8.
Study Type:
Observational
Primary Sponsor:
Institute - AbbVie GK
Condition:
Condition - Ulcerative colitis
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - The clinical effectiveness of risankizumab in patients with moderate to severe ulcerative colitis in real-world clinical practice
Basic objectives2 - Efficacy
Eligibility:
Age-lower limit - 15
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inc...